Literature DB >> 15863464

Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.

Hernán García-Rivello1, Julián Taranda, Matilde Said, Patricia Cabeza-Meckert, Martin Vila-Petroff, Jorge Scaglione, Sergio Ghio, Ju Chen, Cary Lai, Ruben P Laguens, Kent C Lloyd, Cecilia M Hertig.   

Abstract

The neuregulin receptor tyrosine kinase Erb-b4, initially linked to early cardiac development, is shown here to play a critical role in adult cardiac function. In wild-type mice, Erb-b4 protein localized to Z lines and to intercalated disks, suggesting a role in subcellular and intercellular communications of cardiomyocytes. Conditional inactivation of erb-b4 in ventricular muscle cells led to a severe dilated cardiomyopathy, characterized by thinned ventricular walls with eccentric hypertrophy, reduced contractility, and delayed conduction. This cardiac dysfunction may account for premature death in adult erb-b4-knockout mice. This study establishes a critical role for Erb-b4 in the maintenance of normal postnatal cardiac structure and function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863464     DOI: 10.1152/ajpheart.00048.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  57 in total

Review 1.  The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.

Authors:  Brian Wadugu; Bernhard Kühn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

2.  Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Authors:  Ilkka Paatero; Anne Jokilammi; Pekka T Heikkinen; Kristiina Iljin; Olli-Pekka Kallioniemi; Frank E Jones; Panu M Jaakkola; Klaus Elenius
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

3.  A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscle.

Authors:  Federica Santoro; Makoto Sahara
Journal:  Ann Transl Med       Date:  2015-10

Review 4.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

5.  Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling.

Authors:  Yoshikazu Nakaoka; Keigo Nishida; Masahiro Narimatsu; Atsunori Kamiya; Takashi Minami; Hirofumi Sawa; Katsuya Okawa; Yasushi Fujio; Tatsuya Koyama; Makiko Maeda; Manami Sone; Satoru Yamasaki; Yuji Arai; Gou Young Koh; Tatsuhiko Kodama; Hisao Hirota; Kinya Otsu; Toshio Hirano; Naoki Mochizuki
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.

Authors:  Laura Pentassuglia; Michael Graf; Heidi Lane; Yukio Kuramochi; Gregory Cote; Francesco Timolati; Douglas B Sawyer; Christian Zuppinger; Thomas M Suter
Journal:  Exp Cell Res       Date:  2009-02-12       Impact factor: 3.905

7.  The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale.

Authors:  Nirav Patel; Antoni Barrientos; Ralf Landgraf
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 8.  Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.

Authors:  Tolulope A Agunbiade; Raja Y Zaghlol; Ana Barac
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 9.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

10.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.